Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis.
Lack of estrogen affects the urinary tract mainly by diminishing vascular, muscular and epithelial trophism, resulting in negative effects on continence in postmenopausal women. Therefore, the use of estrogens in these patients may revert these alterations and lead to an expressive improvement of the urinary symptoms.


OBJECTIVE
Study the effect of topical estrogen therapy (conjugated equine estrogens, estriol or promestriene) in periurethral vessels detected by Dopplervelocimetric analysis using, as parameters: the number of vessels, resistance and pulsatility indexes, as well as the minimum diastolic value.


METHODS
Forty-one postmenopausal women with stress urinary incontinence were randomized into three groups according to different types of topical estrogen received during 3 months. Group 1 received conjugated equine estrogens, group 2 received estriol and group 3 received promestriene. Periurethral Dopplervelocimetry analysis was done before estrogen administration and during treatment in all groups.


RESULTS
We observed an increase in the number of the periurethral vessels in group 1 and group 2, being higher in group 1 than in group 2. The pulsatility index remained unchanged in all three groups. The resistance index at the periurethral vessels reduced only at the conjugated estrogen group (group 1). In this same group we noticed an increase in the mean minimal diastolic value, meaning a better periurethral vascularization.


CONCLUSIONS
Topical conjugated equine estrogens and estriol were effective in increasing the number of periurethral vessels in postmenopausal women with urinary stress incontinence, with the conjugated equine estrogens being the most effective intervention studied.
UNIFESP - são paulo federal university, São Paulo, Brazil.
S A
SA
Kobata
M J B C
MJ
Girão
E C
EC
Baracat
M
M
Kajikawa
V
V
Di Bella
M G F
MG
Sartori
Z I K
ZI
Jármy-Di Bella
D000282:Administration, Intravaginal; D000368:Aged; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004964:Estriol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000379:methods; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D017078:Laser-Doppler Flowmetry / Q000379:methods; D008875:Middle Aged; D017698:Postmenopause; D018709:Statistics, Nonparametric; D014463:Ultrasonography; D014521:Urethra / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000187:drug effects; D014550:Urinary Incontinence, Stress / Q000000981:diagnostic imaging / Q000188:drug therapy*
D004966:Estrogens, Conjugated (USP); D004958:Estradiol; D004964:Estriol; C013657:promestriene